Bioregenx, Inc.
BioRegenx, Inc. is a U.S.-based developer and distributor of medical test equipment, wellness devices, and science-based nutritional products. The company traces its current form to a series of mergers and acquisitions, including the March 2024 merger that gave the business its current name. Its products are sold nationally through a direct selling channel and are aimed at health professionals, research organizations, and wellness-oriented customers. Recent filings indicate the company is still in a development and turnaround phase, with management focused on rebuilding sales, resolving product issues, and securing additional capital to support operations.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueDiagnostic and testing devices developed and manufactured for health-related use.
Science-based supplements and nutritional offerings sold through the company's network.
Consumer and practitioner wellness devices distributed nationally.
Direct-selling channel and related sales support used to reach end customers and professionals.
Products
Reported · share of revenue- Nutritional87.5 %
- Medical Testing11.2 %
- Wellness Devices1.4 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
BioRegenx sells through a direct-selling model, so its customer base includes end consumers purchasing wellness and nutritional products as well as intermediaries in the health and research ecosystem. The filings specifically mention health professionals and research organizations, which suggests part of demand is professional or semi-professional rather than purely retail. The company also relies on a distributor base, making channel partners an important part of how products reach the market. Product quality and reliability matter because management linked recent sales weakness to issues with the medical testing machine and the effect that had on nutritional sales and the distributor network.
Buy medical test equipment and related wellness products for professional use and patient-facing recommendations.
Purchase testing equipment and science-based products for research or evaluation purposes.
Buy nutritional products and wellness devices through the company's national direct-selling channel.
Support product reach and repeat sales; their engagement is important to the company's sales recovery.
Strategy
Management's near-term focus is on stabilizing the business after the 2024 merger and rebuilding sales momentum. The company is trying to use its combined production and distribution capabilities to create synergies across medical testing, nutritional products, and wellness devices. It also appears to be working through product issues that hurt the distributor base and reduced nutritional sales, which makes product reliability a strategic priority. At the same time, the company is actively seeking additional debt or equity financing to fund working capital and continue development.
Recent sales declines were linked to product issues with the medical testing machine and their spillover effect on nutritional sales.
The company states it will require more capital to fund operations and working capital and may use debt, equity, or strategic arrangements.
The company expects the combination of production activities and the marketing network to create synergies across the group.
Geography
The company states that its products are sold nationally in the United States, and the available filings do not disclose a meaningful international revenue split. That makes the U.S. the core operating market and the main source of demand, channel activity, and regulatory exposure. Because the business is concentrated domestically, changes in U.S. consumer demand, distributor behavior, and product compliance have an outsized effect on results. No country-level revenue breakdown was disclosed in the provided excerpts.
Risks
BioRegenx faces going-concern and financing risk because management says it will likely continue to generate losses and needs additional capital to fund operations. The business is also exposed to product-quality and execution risk, as recent filings tie lower sales to problems with the medical testing machine and the resulting damage to the distributor base. Because the company sells through direct selling and depends on channel partners, any loss of trust or disruption in the network can quickly affect revenue. More broadly, the company faces typical risks for small medical-device and wellness-product businesses, including regulatory scrutiny, product liability, inventory obsolescence, and demand volatility in a competitive consumer health market.
Management states it expects losses and needs additional debt or equity capital, with no assurance funding will be obtained.
The company explicitly linked lower net sales to product issues with the medical testing machine and the effect on nutritional sales.
A concentrated distribution model can amplify the impact of distributor attrition or weak recruitment.
Exposure: Sales volume and customer acquisition
Medical test equipment and wellness products can face compliance, labeling, and safety scrutiny.
Accounting
Judgemental itemsReported net sales depend on the level of returns and credits, which can materially change period-to-period comparability.
Impact: Revenue volatility and margin analysis
The company issued common shares for services, creating non-cash expense that affects operating loss trends.
Impact: Operating expenses and dilution analysis
These items affect reported interest expense and the carrying amount of debt obligations.
Impact: Net loss and leverage assessment
Accounts payable and accrued interest to related parties can signal financing dependence and liquidity stress.
Impact: Cash flow and going-concern evaluation
Similar listed companies
Publicly listed companies with a comparable business focus.
MiMedx Group, Inc
MDXG · Surgical & Medical Instruments & Apparatus
MIMEDX Group develops and commercializes regenerative biologic products used by clinicians to treat chronic wounds, burns, and surgical applications.
Bio Essence Corp
BIOE · Pharmaceutical Preparations
Bio Essence Corp is a California-based holding company whose operating history has centered on health supplements and OEM manufacturing/distribution services.
Biomerica, Inc
BMRA · In Vitro & In Vivo Diagnostic Substances
Regenerex Pharma, Inc.
Pharmaceutical Preparations
Vincerx Pharma, Inc.
Pharmaceutical Preparations
BioCorRx Inc.
BICX · Services-Specialty Outpatient Facilities, NEC
Last updated: 11/08/2026